Aridis Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 37
- Market Cap
- -
- Website
- http://www.aridispharma.com
A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2
Phase 3
Terminated
- Conditions
- Ventilator Associated PneumoniaStaphylococcus Aureus
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Aridis Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05331885
- Locations
- 🇧🇪
Research Site Bel03, Haine-Saint-Paul, Belgium
🇧🇪Research Site Bel02, Ottignies, Belgium
🇧🇪Research Site Bel05, Yvoir, Belgium
Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301
Phase 3
Completed
- Conditions
- Staphylococcus AureusLung InfectionPneumonia, Ventilator-AssociatedInfection, Bacterial
- Interventions
- Other: Placebo
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Aridis Pharmaceuticals, Inc.
- Target Recruit Count
- 174
- Registration Number
- NCT03816956
- Locations
- 🇧🇾
BLR-04, Gomel, Belarus
🇧🇾BLR-01, Minsk, Belarus
🇨🇳CHN-09, Guangzhou, Guangdong, China
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
Phase 1
Recruiting
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Inhaled AR-501Drug: Inhaled Placebo
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Aridis Pharmaceuticals, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT03669614
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Aridis Pharmaceuticals, Inc.
- Target Recruit Count
- 158
- Registration Number
- NCT03027609
- Locations
- 🇺🇸
Research Site 5, Chicago, Illinois, United States
🇺🇸Research Site 9, Royal Oak, Michigan, United States
🇨🇳Research Site 2, Taipei, Taiwan
Study of Single Doses of IV Aerucin in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: Aerucin 20.0 mg/kgBiological: Aerucin 2.0mg/kgBiological: Aerucin 8.0mg/kg
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Aridis Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02486770
- Locations
- 🇺🇸
SNBL-CPC, Baltimore, Maryland, United States
Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)
Phase 1
Completed
- Conditions
- Pneumonia Due to Staphylococcus Aureus
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-05-01
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Aridis Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01589185
- Locations
- 🇧🇪
Site 11, Brussels, Belgium
🇫🇷Site 34, Colombes, France
🇫🇷Site 32, Argenteuil, France
© Copyright 2025. All Rights Reserved by MedPath